Current trends in the treatment of malignant melanoma

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Skin cancer is a frequent malignancy, with melanoma being less common but more lethal than basal and squamous cell carcinomas.
• Melanoma accounts for 3% of skin cancers but 65% of skin cancer-related deaths, highlighting its aggressive nature.
• Understanding melanoma at the molecular level is crucial for developing novel therapeutic strategies and effective drugs.

Purpose of the Study:

• To review current therapeutic approaches for melanoma, including immunotherapy and targeted therapy.
• To emphasize the role of molecular knowledge in designing new protein kinase inhibitors for targeted melanoma treatment.
• To identify future research directions, such as clinical trials for optimizing combination therapy sequencing and data collection.

Main Methods:

• Review of current literature on melanoma molecular biology and therapeutic strategies.
• Analysis of the mechanisms of action for immunotherapy (immune checkpoint blockades) and targeted therapy (protein kinase inhibitors).
• Identification of key signaling pathways involved in melanoma development.

Main Results:

• Current melanoma treatment relies on immunotherapy and targeted therapy, often used in combination.
• Protein kinase inhibitors, informed by molecular structure and pathway knowledge, are a key component of targeted therapy.
• Further clinical trials are needed to optimize treatment combinations and understand their impact on survival and response rates.

Conclusions:

• Detailed molecular insights into melanoma are essential for advancing treatment options.
• The combination of immunotherapy and targeted protein kinase inhibitors represents the current standard of care.
• Future research must focus on clinical validation to refine melanoma treatment strategies and improve patient outcomes.